Update on ConfIdeS Phase 3 trial
-
Update on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patients
Biologic License Application submission expected for 2025
"ConfIdeS trial is expected to conclude in mid-2024."
"To accelerate randomization, Hansa has increased overall site activation up to 25 sites, continued enrollment beyond the targeted 64 patients, ..."
Tjek også: Clinical pipeline update & Commercial update.
"Total cash and equivalents stood at SEK 908 million (USD 83m) end of September 2023 which is expected to finance Hansa’s operations into 2025, as previously guided."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind